UCB's new meds spur sales growth; Otsuka nabs NICE backing for kidney med;

> Belgium's UCB hiked its full-year financial outlook on strong growth of three of its new drugs--Cimzia, Vimpat and Neupro--and ongoing sales of its off-patent epilepsy med Keppra. Report

> Otsuka's Jinarc, a treatment for autosomal dominant polycystic kidney disease, won backing from England's cost-effectiveness watchdogs. Report

> Merck & Co. ($MRK) said its price cut on Remicade in the U.K. will save England's National Health Service millions of pounds. Report

And Finally... More than three-fourths of Americans say the cost of prescription drugs for serious diseases is their chief health concern, a Kaiser Family Foundation poll found. Report